The UK Medicines and Healthcare products Regulatory Agency (MHRA) published its draft Rare Disease Therapies Regulatory Framework on 21 May 2026 ...
The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has unveiled a new business plan to build on the launch of a three-year corporate plan. The new plan will build on the 2023 ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has published draft regulations reforming pre-market requirement for medical ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has shared guidance on how extreme heat such as that the UK is ...
The UK’s medicines regulator has set out plans to accelerate the development and approval of treatments for rare diseases ...
Approval mechanisms must be grounded in patient need and population health In April 2026, the UK government announced a new pathway to expedite the availability of new medicines in the NHS.1 The joint ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved teprotumumab (Tepezza, Amgen) as the first treatment to be licensed in the UK for adults with moderate-to-severe thyroid eye ...
Launched today by the Medicines and Healthcare products Regulatory Agency (the MHRA), the seventh annual #MedSafetyWeek is running until 13 November to encourage widespread public engagement and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results